Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative but strong event-driven momentum after FDA agreed on a resubmission path for RP1 plus nivolumab melanoma BLA, with supportive ASCO clinical updates and roughly 132% gain over 20 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Failed Rebounds ⢠Key Support Test ⢠Overhead Resistance Support Level: $9.50 Resistance Level: $11.00-$11.60 REPL is in a fragile short-term downtrend after failing repeatedly at $11.0-$11.6, with near-term support around $9.5 that must hold to prevent further weakness.
Sentiment & News
Key News Insights: ⢠FDA acceptance ⢠August decision ⢠Legal scrutiny Replimune's RP1 melanoma filing was accepted by the FDA, keeping a potential August decision on track, though an advisory review and shareholder investigation add near-term uncertainty.
AI Summary
Replimune is now a near-term FDA binary trade rather than a long-duration platform story: approval of the resubmitted RP1 BLA could sharply re-rate the stock, but any FDA pushback would likely hit a cash-burning, single-asset biotech with limited downside resilience.
Description
Replimune Group, Inc. is a biotechnology company developing oncolytic immuno-gene therapies for cancer using its proprietary Immunotherapy platform. Its lead candidate, RP1, is a selectively replicating herpes simplex virus 1 therapy being evaluated in clinical trials for solid tumors and cutaneous squamous cell carcinoma, alongside earlier-stage programs including RP2 and RP3. The company was founded in 2015 and is based in Woburn, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 22 | Jun 29 | REPL | Replimune Group, Inc. | Speculative but strong event-driven momentum after FDA agreed on a resubmission path for RP1 plus nivolumab melanoma BLA, with supportive ASCO clinical updates and roughly 132% gain over 20 trading days. | Closed | +0.2% |
| Jun 10 | Jun 17 | REPL | Replimune Group, Inc. | Speculative biotech momentum candidate: stock rose about 113% over 21 trading days, helped by 2026-05-29 FDA alignment on a path forward for RP1 plus nivolumab BLA resubmission/reconsideration and ASCO clinical updates on 2026-05-30 and 2026-05-31. | Closed | +18.1% |